Endocyte Inc. buy melinda
Start price
13.03.17
/
50%
€2.30
Target price
12.05.17
€3.61
Performance (%)
8.63%
End price
12.05.17
€2.50
Summary
This prediction ended on 12.05.17 with a price of €2.50. With a performance of 8.63%, the BUY prediction by melinda for Endocyte Inc. closed with a slight gain. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Endocyte Inc. | - | - | - | - |
| iShares Core DAX® | -3.033% | -0.013% | 11.953% | 15.609% |
| iShares Nasdaq 100 | -3.554% | -2.546% | 30.128% | 44.540% |
| iShares Nikkei 225® | -3.938% | 2.183% | 11.741% | 8.345% |
| iShares S&P 500 | -1.517% | -0.882% | 25.752% | 42.388% |
Comments by melinda for this prediction
In the thread Endocyte Inc. diskutieren
Biopharma
Endocyte, Inc. ist ein biopharmazeutisches Unternehmen in der Entwicklung von gezielten Therapien zur Behandlung von Krebs und Entzündungs diseases.It engagiert verwendet eine patentierte Technologie , um neue Kleinmolekül - Konjugate von Medikamenten und Begleiter bildgebenden Diagnostik zu schaffen für personalisierte gezielte